
Opinion|Videos|July 11, 2024
Exploring Results from CAPItello-291 Trial
William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.
Advertisement
Episodes in this series

- In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the
CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?- What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
- How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
3
Pediatric Atopic Dermatitis Treatment Selection: Biologics vs Nonsteroidal Topical Therapies
4
New WHO Report Sounds Alarm on Antimicrobial Resistance
5